Ana Christina Garrido-Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Christina Garrido-Castro has a total of 446 co-authors. Here are the top co-authors by number of shared publications:
Ian E. Krop
66 shared publicationsSara M. Tolaney
Dana-Farber Cancer Institute, Boston, USA
66 shared publications- Justin M. Balko
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
46 shared publications - Paula I. Gonzalez-Ericsson
Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, USA
46 shared publications Brent N. Rexer
45 shared publicationsIngrid A. Mayer
45 shared publications
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 38 (6) , 471-478
Time-of-day administration of immune checkpoint inhibitors: current clinical evidence and future directions for breast cancer
Purpose of review: Immune checkpoint inhibitors (ICIs) are increasingly used in breast cancer, particularly in triple-negative breast cancer. This review summarizes the biologic rationale and emerging clinical evidence for time-of-day ICI administration and discusses its implications for breast cancer. Recent findings: Circadian rhythms provide a biologic rationale for time-dependent immunotherapy efficacy. Several retrospective studies across multiple tumor types have suggested associations between earlier ICI administration and improved outcomes, although findings remain inconsistent. Breast cancer-specific data are expanding but remain heterogeneous, with signals varying by treatment setting, endpoint, timing definition, and tumor immune contexture. These findings suggest that treatment timing should be interpreted in the context of the broader treatment platform in which immunotherapy is delivered, including concomitant chemotherapy and supportive medications, as well as host circadian state and tumor immune contexture. An ongoing prospective study aims to integrate circadian, systemic immune, and tumor-based assessments to elucidate the biological and clinical relevance of treatment timing in breast cancer. Summary: Current evidence does not establish an optimal infusion window for breast cancer treatment. Prospective studies integrating clinical outcomes with circadian, systemic immune, and tumor-based analyses are needed to determine whether treatment timing can be developed into a biologically informed strategy.
- 1 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 38 (6) , 471-478
Time-of-day administration of immune checkpoint inhibitors: current clinical evidence and future directions for breast cancer
Purpose of review: Immune checkpoint inhibitors (ICIs) are increasingly used in breast cancer, particularly in triple-negative breast cancer. This review summarizes the biologic rationale and emerging clinical evidence for time-of-day ICI administration and discusses its implications for breast cancer. Recent findings: Circadian rhythms provide a biologic rationale for time-dependent immunotherapy efficacy. Several retrospective studies across multiple tumor types have suggested associations between earlier ICI administration and improved outcomes, although findings remain inconsistent. Breast cancer-specific data are expanding but remain heterogeneous, with signals varying by treatment setting, endpoint, timing definition, and tumor immune contexture. These findings suggest that treatment timing should be interpreted in the context of the broader treatment platform in which immunotherapy is delivered, including concomitant chemotherapy and supportive medications, as well as host circadian state and tumor immune contexture. An ongoing prospective study aims to integrate circadian, systemic immune, and tumor-based assessments to elucidate the biological and clinical relevance of treatment timing in breast cancer. Summary: Current evidence does not establish an optimal infusion window for breast cancer treatment. Prospective studies integrating clinical outcomes with circadian, systemic immune, and tumor-based analyses are needed to determine whether treatment timing can be developed into a biologically informed strategy.
- 30 July 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 218 (2) , 26
Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer
- 30 July 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 218 (2) , 26
Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Combination of RB40.34 + anti-PD-1 results in response to treatment in TNBC.
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Combination of RB40.34 + anti-PD-1 results in response to treatment in TNBC.
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Gating strategies used to identify different T cell types in mouse
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Gating strategies used to identify different T cell types in mouse
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Mouse T-cell exhaustion flow panel
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Mouse T-cell exhaustion flow panel
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
PSGL-1 blockade produces similar protective effects against exhaustion in CD4+ and CD8+ effector T cells as P-selectin inhibition
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
PSGL-1 blockade produces similar protective effects against exhaustion in CD4+ and CD8+ effector T cells as P-selectin inhibition
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Tumor-associated platelets (TAP) exhaust CD4+ and CD8+ effector T cells in human. A, Schematic of the T-cell isolation and platelet coculture experiment. SF RPMI, serum-free RPMI. Flow cytometry was used to quantify functionality of (B) CD4+ and (C) CD8+ effector T cells and exhaustion of (D) CD4+ and (E) CD8+ effector T cells in the coculture. Data are representative of three independent experiments. Statistical significance was determined using a one-way ANOVA followed by the Tukey multiple-comparison test. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Tumor-associated platelets (TAP) exhaust CD4+ and CD8+ effector T cells in human. A, Schematic of the T-cell isolation and platelet coculture experiment. SF RPMI, serum-free RPMI. Flow cytometry was used to quantify functionality of (B) CD4+ and (C) CD8+ effector T cells and exhaustion of (D) CD4+ and (E) CD8+ effector T cells in the coculture. Data are representative of three independent experiments. Statistical significance was determined using a one-way ANOVA followed by the Tukey multiple-comparison test. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Mouse CRP-activated KO-P-selectin activated platelets do not affect CD4+ and CD8+ Effector T cells
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Mouse CRP-activated KO-P-selectin activated platelets do not affect CD4+ and CD8+ Effector T cells
- Open Access
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Tumor-associated platelets (TAP) exhaust CD4+ and CD8+ effector mouse T cells. A, Schematic of the T-cell isolation and platelet coculture experiment. Flow cytometry was used to quantify the functionality of (B) CD4+ and (C) CD8+ effector T cells and exhaustion of (D) CD4+ and (E) CD8+ effector T cells. SF RPMI, serum-free RPMI. F, Schematic of the T-cell and AT-3 coculture experiment. Levels of Zombie NIR caspase 3/7 dye detected over 48 hours. Flow cytometry to detect death in (G) CD3+ T cells and (H) AT-3 tumor cells. Data are representative of three independent experiments. Statistical significance was determined using a one-way ANOVA followed by the Tukey multiple-comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 10 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway
Tumor-associated platelets (TAP) exhaust CD4+ and CD8+ effector mouse T cells. A, Schematic of the T-cell isolation and platelet coculture experiment. Flow cytometry was used to quantify the functionality of (B) CD4+ and (C) CD8+ effector T cells and exhaustion of (D) CD4+ and (E) CD8+ effector T cells. SF RPMI, serum-free RPMI. F, Schematic of the T-cell and AT-3 coculture experiment. Levels of Zombie NIR caspase 3/7 dye detected over 48 hours. Flow cytometry to detect death in (G) CD3+ T cells and (H) AT-3 tumor cells. Data are representative of three independent experiments. Statistical significance was determined using a one-way ANOVA followed by the Tukey multiple-comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.